Latest Stories from Health

Macrophage Therapeutics to Expand Efforts Into CNS Diseases

2015-03-20T12:11:08-07:00

- Initiative based on data that targeted delivery technology crosses blood brain barrier -

Oral OTEZLA® (apremilast) Long-Term Safety and Efficacy Data in Patients with Moderate to Severe Plaque Psoriasis Presented at AAD

2015-03-20T10:00:24-07:00

Improvements in the severity of preexisting nail, scalp and palmoplantar psoriasis achieved at week 16 were maintained in OTEZLA responders through week 52 in ESTEEM 2 OTEZLA improved the severity of palmoplantar psoriasis at week 16 in a subset of patients across three trials Long-term safety profile for up to 104 weeks in ESTEEM 1 was consistent with previously reported data from OTEZLA clinical trial programs, with no new safety signals and no clinically meaningful changes in laboratory values

Pfizer Announces Oral Tofacitinib Meets Primary Endpoints In Pivotal Phase 3 Psoriasis Trials

2015-03-20T10:00:08-07:00

Detailed Results from OPT Pivotal Studies Along with Integrated Analysis of Safety Data from Psoriasis Global Clinical Development Program Presented at 73rd American Academy of Dermatology (AAD) Annual Meeting

Innate™ Potato Receives FDA Safety Clearance

2015-03-20T09:01:16-07:00

Varieties Contain Beneficial Traits Without Foreign Genes

Pernix Therapeutics Inc. to Present at the Deutsche Bank Pharma 1-on-1 Day in Denver, Colorado

2015-03-20T08:33:07-07:00

FDA Approves BIOTRONIK Eluna Pacemaker System with Full-Body ProMRI Technology

2015-03-20T06:29:16-07:00

Second Generation Single- and Dual-Chamber Pacemakers That Give Patients Access to MRI Scans Now Available in the U.S.

Biogen Idec Presents Positive Interim Results from Phase 1B Study of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) at 2015 AD/PD™ Conference

2015-03-20T02:35:09-07:00

– Analysis Demonstrates Acceptable Safety, Statistically Significant Reduction of Amyloid Plaque Levels and Benefit on Exploratory Clinical Endpoints – – Aducanumab Clinical Development Program to Advance to Phase 3 –

USDA Adds bioMérieux TEMPO® System to Microbiology Laboratory Guidebook, the Standard-Setting Guideline for Food-Safety Testing in the U.S.

2015-03-19T13:59:01-07:00

TEMPO®’s automated food quality testing will help improve food safety nationwide

Galderma Announces Positive Phase 3 Trial Results of Investigational Adapalene 0.3%/Benzoyl Peroxide 2.5% (0.3% A/BPO) for the Treatment of Acne

2015-03-19T11:13:09-07:00

Pivotal Data to be Presented at This Year’s American Academy of Dermatology Meeting

GlycoMimetics to Present First Preclinical Data on E-selectin-CXCR4 Dual Antagonist for Cancer Indications at AACR Annual Meeting 2015

2015-03-19T06:30:16-07:00

Prestium Pharma, Inc. Announces Plans for Release of Improved OLUX® (Clobetasol Propionate) Foam

2015-03-19T05:00:43-07:00

Prestium Pharma, Inc. announced it is planning to launch an improved version of OLUX® (clobetasol propionate), 0.05% Foam.

Svelte Medical Systems Secures Financing; Richard Dakers Joins Board

2015-03-19T04:30:02-07:00

All-insider round of investment funds ongoing operations and upcoming commercial activities in Europe. Richard Dakers of the West Health Investment Fund joins the company Board of Directors.

CorMatrix® CanGaroo™ Secures International Approval for South America

2015-03-18T12:57:08-07:00

CorMatrix Extends Distribution of Its Implantable Device to Buenos Aires Based, Demedic

Novan Achieves Target Enrollment for Phase 2 Acne Study

2015-03-18T06:45:09-07:00

Company Positioned to Expand Clinical Dermatology Programs in 2015

PsychoGenics Obtains a License to α-synuclein Transgenic Mouse Models of Parkinson´s disease

2015-03-18T05:00:51-07:00